MOTIVATION LETTER The Conjunctive Consolidation Threshold model, developed independently over eighteen months in Lagos, specifies a tripartite pharmacological mechanism for preventing reward-memory encoding in addiction. Three sole-authored preprints on OSF and Zenodo formalise the framework: a foundational paper, a mathematical specification using ODE/RK45 solvers, and a Bayesian population dynamics model with a clinical trial architecture. The model achieves an encoding probability reduction from 0.855 to 0.122, an 85.8 percent decrease, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed. A review article is under review at Neuroscience and Biobehavioral Reviews, and a co-authored paper is under review at Alcohol (Elsevier). These results were produced without institutional affiliation, using personal computational resources and open-source tooling. The EMBL ARISE2 Fellowship targets researchers who develop technology and methods for research infrastructures. My work fits this mandate directly. I built three platforms during the same period: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions using persistent homology and bipartite simplicial complexes with a hERG cardiotoxicity MVP, and GATE for BCI neural-stimulation safety evaluation, released under Apache 2.0. These platforms demonstrate method development, software engineering, and deployment skills. A provisional patent on the CCT core architecture is filed for Q3 2026. Endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard who provided my arXiv endorsement, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU confirm the scientific validity of the approach. My computational skills include Python with scipy, numpy, PyMC for MCMC, R, TDA with Ripser and Gudhi, NEURON and Brian2 for neural simulation, AlphaFold, RDKit, ADMET and QSAR pipelines, GROMACS, AutoDock, Nextflow for HPC workflows, and Supabase with Postgres for database infrastructure. I am a Nigerian national, currently in Lagos, holding a B.Pharm from the University of Ibadan with a CGPA of 5.1 out of 7.0, a German equivalent of 1.9, and a PCN pharmacist license. I am applying for MSc programmes starting October 2026 at the Medical University of Graz in Austria. The ARISE2 Fellowship would allow me to transition from independent research into a structured European research infrastructure environment, developing computational tools for addiction neuroscience that can be deployed across EMBL member states and made accessible to researchers in low- and middle-income countries. SHORT ESSAY: RESEARCH ACHIEVEMENTS AND TECHNOLOGY DEVELOPMENT My primary research achievement is the Conjunctive Consolidation Threshold model, a framework that specifies how three pharmacological agents administered in a timed sequence can prevent the encoding of reward-associated memories in addiction. The model was validated using ODE/RK45 numerical integration and Bayesian MCMC methods. Encoding probability dropped from 0.855 to 0.122, a reduction of 85.8 percent. The combination showed super-additivity of 12.8 percentage points beyond the sum of individual effects. All five pre-registered hypotheses were confirmed. The formal mathematical specification and Bayesian population dynamics model are published as preprints with DOIs on OSF and Zenodo. Three software platforms demonstrate technology development. IMPRINT screens compounds for addiction liability using pharmacokinetic and pharmacodynamic parameters. TOPOLOGIX applies topological data analysis with persistent homology and bipartite simplicial complexes to drug-protein interaction networks, with a working MVP for hERG cardiotoxicity prediction. GATE evaluates safety of BCI neural-stimulation protocols and is released under Apache 2.0. These platforms required integration of computational chemistry, neural simulation, and database engineering. A provisional patent on the CCT core architecture is in process for Q3 2026. Endorsements from four leading computational and affective neuroscientists validate the direction. A review article is under review at Neuroscience and Biobehavioral Reviews and a co-authored paper at Alcohol (Elsevier). These outputs were produced without a PhD, without institutional laboratory access, and without research funding, using open-source tools and personal hardware in Lagos. SHORT ESSAY: MOTIVATION FOR RESEARCH INFRASTRUCTURES CAREER Research infrastructures depend on people who can build tools that other scientists use. My three platforms IMPRINT, TOPOLOGIX, and GATE are exactly that: reusable, documented, open-source software for addiction liability screening, topological drug-protein interaction analysis, and BCI safety evaluation. I want to spend my career designing, maintaining, and improving such infrastructures rather than pursuing a traditional tenure-track academic line. The EMBL ARISE2 Fellowship is designed for this path. EMBL operates some of the world's most advanced biological research infrastructures, from structural biology beamlines to bioinformatics resources. My experience building computational tools from scratch in a resource-constrained environment gives me a practical orientation toward reliability, documentation, and user accessibility. I understand what it means to produce software that works without institutional IT support. My background as a licensed pharmacist and computational researcher positions me to bridge pharmacology and data science within a research infrastructure context. I want to develop tools that help addiction researchers across Europe and Africa access validated computational models, screening pipelines, and simulation environments. The ARISE2 Fellowship would provide the training, mentorship, and network to turn this into a career. SHORT ESSAY: PROPOSED TECHNOLOGY OR METHOD DEVELOPMENT PROJECT I propose to develop an open-source computational platform for predicting addiction liability of novel compounds using the CCT framework. The platform will integrate three components: a pharmacokinetic simulator using ODE/RK45 solvers parameterised for human and rodent models, a Bayesian MCMC module for estimating individual-level encoding probability from behavioural data, and a topological data analysis module using TOPOLOGIX to screen compounds for off-target interactions at reward-circuit receptors. The platform will be built in Python with a Supabase and Postgres backend, containerised with Docker, and deployable on EMBL's HPC infrastructure using Nextflow. Documentation will follow EMBL's standards for research software. The project will produce a web-accessible interface for researchers to run simulations without programming, plus an API for programmatic access. This project directly supports EMBL's mission to provide advanced research infrastructure to the life sciences community. Addiction neuroscience currently lacks standardised computational tools for preclinical compound screening. The platform would fill that gap, reduce animal experimentation, and accelerate identification of safer treatments. The work builds on my existing codebase and can produce a working prototype within the fellowship period. CHECKLIST - [ ] Confirm PhD eligibility: verify whether EMBL ARISE2 accepts applicants who will begin a PhD programme before the fellowship start date, or whether a completed PhD is strictly required - [ ] Obtain official transcripts from University of Ibadan with German grade conversion certificate - [ ] Secure letters of recommendation from Kent Berridge, Samuel Gershman, or Nathaniel Daw - [ ] Prepare a two-page CV formatted to EMBL ARISE2 specifications - [ ] Write a detailed project proposal (2-3 pages) for the CCT computational platform - [ ] Gather proof of provisional patent filing for CCT core architecture - [ ] Collect DOIs and PDFs for all three preprints and the two papers under review - [ ] Prepare a portfolio page for IMPRINT, TOPOLOGIX, and GATE with documentation links - [ ] Verify mobility requirements: confirm ability to relocate to an EMBL site in Europe - [ ] Check deadline on the EMBL ARISE2 official website (the URL provided is a third-party aggregator) EDITOR NOTES - Eligibility is the critical risk. The deep research states a PhD is required before starting the fellowship. Eniola does not have a PhD and is applying for MSc programmes starting October 2026. If the fellowship requires a completed PhD, this application cannot proceed unless Eniola can secure a PhD position that finishes before the fellowship start date, which is unlikely. Verify the official EMBL ARISE2 eligibility page directly. - The profile lists a provisional patent for Q3 2026 but does not specify the jurisdiction or patent office. This needs to be confirmed and documented before submission. - Endorsements from Berridge, Gershman, Daw, and Mattar are listed but no letters of recommendation have been obtained. Eniola should confirm each person's willingness to write and their familiarity with his work. - The proposed project section is speculative. Eniola should refine the technical scope in consultation with potential EMBL supervisors to ensure feasibility and alignment with available infrastructure. - The profile does not specify any prior collaboration with EMBL or any EMBL scientist. A connection to a potential host group would strengthen the application significantly.